| Guillermo A Herrera, MD | |
|
2451 University Hospital Dr Fl 1, Mobile, AL 36617-2300 | |
| (251) 471-7790 | |
| (251) 471-7096 |
| Full Name | Guillermo A Herrera |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 49 Years |
| Location | 2451 University Hospital Dr Fl 1, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558375220 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Usa Health University Hospital | Mobile, AL | Hospital |
| Palm Beach Gardens Medical Center | Palm beach gardens, FL | Hospital |
| Jupiter Medical Center | Jupiter, FL | Hospital |
| Medstar Southern Maryland Hospital Center | Clinton, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Usa Health Physician Billing Services Llc | 9931436912 | 266 |
News Archive
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Since the emergence of the first AIDS cases in the early 1980s, an infectious wave has spread over Switzerland. Every year, several hundred people are infected with the HI-virus which triggers the acquired immunodeficiency syndrome, AIDS. Does the infection spread according to a particular pattern? Do these patterns vary among the transmission groups such as drug addicts, homosexual or heterosexual persons?
If chromosomes snuggle up too closely at the wrong times, the results can be genetic disaster.
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).
› Verified 5 days ago
| Entity Name | University Of South Alabama |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992746838 PECOS PAC ID: 3072425149 Enrollment ID: O20040115000773 |
News Archive
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Since the emergence of the first AIDS cases in the early 1980s, an infectious wave has spread over Switzerland. Every year, several hundred people are infected with the HI-virus which triggers the acquired immunodeficiency syndrome, AIDS. Does the infection spread according to a particular pattern? Do these patterns vary among the transmission groups such as drug addicts, homosexual or heterosexual persons?
If chromosomes snuggle up too closely at the wrong times, the results can be genetic disaster.
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).
› Verified 5 days ago
| Entity Name | Usa Health Physician Billing Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720645468 PECOS PAC ID: 9931436912 Enrollment ID: O20190814000827 |
News Archive
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Since the emergence of the first AIDS cases in the early 1980s, an infectious wave has spread over Switzerland. Every year, several hundred people are infected with the HI-virus which triggers the acquired immunodeficiency syndrome, AIDS. Does the infection spread according to a particular pattern? Do these patterns vary among the transmission groups such as drug addicts, homosexual or heterosexual persons?
If chromosomes snuggle up too closely at the wrong times, the results can be genetic disaster.
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).
› Verified 5 days ago
| Entity Name | Usa Health - Mci Business Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952972812 PECOS PAC ID: 6800290305 Enrollment ID: O20210805001329 |
News Archive
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Since the emergence of the first AIDS cases in the early 1980s, an infectious wave has spread over Switzerland. Every year, several hundred people are infected with the HI-virus which triggers the acquired immunodeficiency syndrome, AIDS. Does the infection spread according to a particular pattern? Do these patterns vary among the transmission groups such as drug addicts, homosexual or heterosexual persons?
If chromosomes snuggle up too closely at the wrong times, the results can be genetic disaster.
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Guillermo A Herrera, MD Po Box 40480, Mobile, AL 36640-0480 Ph: (251) 434-3626 | Guillermo A Herrera, MD 2451 University Hospital Dr Fl 1, Mobile, AL 36617-2300 Ph: (251) 471-7790 |
News Archive
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a "less is more" approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro's research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Since the emergence of the first AIDS cases in the early 1980s, an infectious wave has spread over Switzerland. Every year, several hundred people are infected with the HI-virus which triggers the acquired immunodeficiency syndrome, AIDS. Does the infection spread according to a particular pattern? Do these patterns vary among the transmission groups such as drug addicts, homosexual or heterosexual persons?
If chromosomes snuggle up too closely at the wrong times, the results can be genetic disaster.
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company announced today that it has published results in the American Journal of Respiratory and Critical Care Medicine from its double-blind, placebo-controlled, randomized Phase IIa study of ALN-RSV01 in lung transplant patients naturally infected with respiratory syncytial virus (RSV).
› Verified 5 days ago
Dr. Lloyd Gardner, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Dr. Lee Fucich, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Cir, Mobile, AL 36607 Phone: 251-460-0326 Fax: 251-460-2846 | |
Elizabeth A. Manci, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1700 Center St, Pathology, Mobile, AL 36604 Phone: 251-415-1612 Fax: 251-415-1003 | |
Carole Boudreaux, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Pathology, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7715 | |
Jonathan Newsom, Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-470-9912 | |
Dr. Rodney Edwin Shackelford, DO Pathology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr, Mobile, AL 36617 Phone: 251-471-7790 Fax: 251-471-7096 | |
Eugene Hart, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 2451 Fillingim St, Department Of Pathology, Mobile, AL 36617 Phone: 251-471-7026 |